Aristada and Vyvanse drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Aristada (aripiprazole lauroxil) and Vyvanse (lisdexamfetamine dimesylate). Common drug interactions include injection site pain among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Aristada and Vyvanse. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Aristada?

Aristada has active ingredients of aripiprazole lauroxil. eHealthMe is studying from 4,234 Aristada users. Check the latest studies of Aristada.

What is Vyvanse?

Vyvanse has active ingredients of lisdexamfetamine dimesylate. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 35,868 Vyvanse users. Check the latest studies of Vyvanse.

On Jul, 12, 2026

16 people who take Aristada and Vyvanse together, and have interactions are studied.

What are the common drug interactions of Aristada and Vyvanse, by gender? *:

female:

Injection site pain
Acne (skin problems that cause pimples)
Decreased appetite
Nausea (feeling of having an urge to vomit)
Somnolence (a state of near-sleep, a strong desire for sleep)
Vomiting
Erythema (redness of the skin)
Injection site erythema (redness at injection site)
Injection site induration
Injection site mass

male:

Nausea (feeling of having an urge to vomit)
Pain in extremity
Suicidal ideation
Injection site bruising
Akathisia (a movement disorder characterized by a feeling of inner restlessness)
Blood creatinine increased
Blood glucose increased
Constipation
Drug ineffective
Granulocyte count increased

What are the common drug interactions of Aristada and Vyvanse, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Affective disorder (mental disorder)
Aggression
Delusion (a false belief or opinion)
Impaired driving ability
Irritability
Personality disorder
Psychotic disorder
Suicidal ideation
Drug ineffective

20-29:

Granulocyte count increased
Haematocrit decreased
Haemoglobin decreased
Injection site abscess
Injection site erythema (redness at injection site)
Injection site infection
Injection site mass
Injection site pain
Injection site reaction
Injection site swelling

30-39:

Acne (skin problems that cause pimples)
Decreased appetite
Injection site pain
Somnolence (a state of near-sleep, a strong desire for sleep)
Nausea (feeling of having an urge to vomit)
Vomiting

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Bipolar Disorder (mood disorder): 4 people, 25.00%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 3 people, 18.75%
Schizoaffective Disorder Bipolar Type (mental illness featuring schizophrenia and a mood disorder with mania): 2 people, 12.50%
Schizoaffective Disorder (a mental disorder characterized by disordered thought): 2 people, 12.50%
Affective Disorder (mental disorder): 2 people, 12.50%
Stress And Anxiety: 1 person, 6.25%
Sleep Disorder: 1 person, 6.25%
Nightmares (unpleasant dreams): 1 person, 6.25%
Major Depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings): 1 person, 6.25%
Drug Dependence: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Aristada and Vyvanse?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously